108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
不同序贯方案的 mFOLFIRINOX（或 SOXIRI）与吉西他滨联合白蛋白结合型紫杉醇在不可切除胰腺癌中的疗效和安全性
Authors Huang S, Huang L, Zhang D, Jiang Q, Wang F, Guo G
Received 24 April 2025
Accepted for publication 28 July 2025
Published 2 October 2025 Volume 2025:14 Pages 1097—1110
DOI https://doi.org/10.2147/ITT.S530434
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Jadwiga Jablonska
Silan Huang,1,* Lingli Huang,1,* Dongsheng Zhang,2 Qi Jiang,1 Fenghua Wang,2 Guifang Guo1
1VIP Department, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China; 2Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Guifang Guo, VIP Department, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China, Email guogf@sysucc.org.cn Fenghua Wang, Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China, Email wangfh@sysucc.org.cn
Aim: This study aimed to evaluate and compare the therapeutic efficacy and adverse effects of two sequential treatment strategies in patients with unresectable advanced pancreatic cancer (aPC), albumin-bound-paclitaxel plus gemcitabine administered follow by mFOLFIRINOX or SOXIRI (AG-F(S)FXm) versus the reverse sequence regimen F(S)FXm-AG.
Methods: In this retrospective analysis, patients with unresectable advanced pancreatic cancer (aPC) who received either AG-F(S)FXm or F(S)FXm-AG were included. Key endpoints were overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Survival outcomes were assessed using Kaplan-Meier curves, and differences between groups were examined through hazard ratios (HR) and corresponding p-values.
Results: A total of 107 patients were analyzed, including 49 who underwent AG-F(S)FXm and 58 who received F(S)FXm-AG. The median OS was 14.60 months for F(S)FXm-AG and 12.20 months for AG-F(S)FXm (HR: 1.04, 95% CI: 0.69– 1.57, p= 0.86). Median PFS1, median PFS2 and median total PFS (tPFS) were 5.20 months versus 4.83 months (HR: 0.81, 95% CI: 0.54– 1.21, p= 0.3), 4.53 months versus 5.77 months (HR: 1.15, 95% CI: 0.71– 1.88, p= 0.60) and 13.80 months versus 12.80 months (HR: 0.90, 95% CI: 0.55– 1.48, p= 0.67) for F(S)FXm-AG versus AG-F(S)FXm. Given their comparable efficacy, we further compared the safety profiles of both regimens. The toxicity profiles differed between the two sequential treatments. Leukopenia was more common with first-line AG, while gastrointestinal toxicity, fatigue, and sensory neuropathy were more frequent with first-line F(S)FXm. Additionally, elevated aspartate aminotransferase was more often reported with second-line AG.
Conclusion: Both AG-F(S)FXm and F(S)FXm-AG demonstrated comparable efficacy in treating aPC, with F(S)FXm-AG showing a trend toward improved outcomes. The choice of sequential treatment should be guided by toxicity profiles and patient-specific factors. Further prospective studies are warranted to optimize treatment sequencing and personalize therapy for improved patient outcomes.
Keywords: advanced pancreatic cancer, AG, mFOLFIRINOX, SOXIRI and efficacy
1VIP Department, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China; 2Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Guifang Guo, VIP Department, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China, Email guogf@sysucc.org.cn Fenghua Wang, Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China, Email wangfh@sysucc.org.cn
Aim: This study aimed to evaluate and compare the therapeutic efficacy and adverse effects of two sequential treatment strategies in patients with unresectable advanced pancreatic cancer (aPC), albumin-bound-paclitaxel plus gemcitabine administered follow by mFOLFIRINOX or SOXIRI (AG-F(S)FXm) versus the reverse sequence regimen F(S)FXm-AG.
Methods: In this retrospective analysis, patients with unresectable advanced pancreatic cancer (aPC) who received either AG-F(S)FXm or F(S)FXm-AG were included. Key endpoints were overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Survival outcomes were assessed using Kaplan-Meier curves, and differences between groups were examined through hazard ratios (HR) and corresponding p-values.
Results: A total of 107 patients were analyzed, including 49 who underwent AG-F(S)FXm and 58 who received F(S)FXm-AG. The median OS was 14.60 months for F(S)FXm-AG and 12.20 months for AG-F(S)FXm (HR: 1.04, 95% CI: 0.69– 1.57, p= 0.86). Median PFS1, median PFS2 and median total PFS (tPFS) were 5.20 months versus 4.83 months (HR: 0.81, 95% CI: 0.54– 1.21, p= 0.3), 4.53 months versus 5.77 months (HR: 1.15, 95% CI: 0.71– 1.88, p= 0.60) and 13.80 months versus 12.80 months (HR: 0.90, 95% CI: 0.55– 1.48, p= 0.67) for F(S)FXm-AG versus AG-F(S)FXm. Given their comparable efficacy, we further compared the safety profiles of both regimens. The toxicity profiles differed between the two sequential treatments. Leukopenia was more common with first-line AG, while gastrointestinal toxicity, fatigue, and sensory neuropathy were more frequent with first-line F(S)FXm. Additionally, elevated aspartate aminotransferase was more often reported with second-line AG.
Conclusion: Both AG-F(S)FXm and F(S)FXm-AG demonstrated comparable efficacy in treating aPC, with F(S)FXm-AG showing a trend toward improved outcomes. The choice of sequential treatment should be guided by toxicity profiles and patient-specific factors. Further prospective studies are warranted to optimize treatment sequencing and personalize therapy for improved patient outcomes.
Keywords: advanced pancreatic cancer, AG, mFOLFIRINOX, SOXIRI and efficacy